ADMA Biologics reviews consolidated net loss of $15.

We commenced and finished patient enrollment in our pivotal Stage III clinical study for RI-002 in patients who have problems with Primary Immune Deficiency Diseases . We also completed our Initial Public Offering in October 2013, increasing gross proceeds of over $29 million, extending our money runway into 2016. Anticipated milestones for 2014 consist of announcing preliminary Stage III data for RI-002, seeking to list our common share on the NASDAQ market and continuing the expansion and ongoing development of our ADMA BioCenters' facilities which have continued to produce year-over-year revenue increases,’ mentioned Adam Grossman, ADMA Biologics President and CEO. 2013 Accomplishments Finished and Commenced Enrollment of Pivotal Phase III Clinical Study of RI-002 Completed IPO Raising Over $29 Million of Gross Proceeds Secured $5 Million Mortgage From Hercules Technology Growth Capital Presented Human and Animal, Clinical and Laboratory Data at the RSV Vaccines for the World 2013 Conference ADMA BioCenters Received German Wellness Certification on the market of Resource Plasma in Europe 2014 Achievements and Anticipated Milestones Expansion Underway of ADMA BioCenters Plasma Collection Operations Increased Hercules Technology Development Capital Loan by $10 Million Intend to File Biologics License Software for New ADMA BioCenters Plasma Collection Facility Intend to Apply to List ADMA Biologics Common Stock on the NASDAQ Market Plan to Announce Preliminary Data from Pivotal Phase III Research of RI-002 in PIDD Patients Related StoriesDeaths from avoidable risk factors: an interview with Dr Ali Mokdad, IHMEOJ Bio at Medica 2015 – Point of Care diagnostics' function in reducing antibiotics prescribingCombatting viral and bacterial lung infections with volatile anesthetics: an interview with Dr Chakravarthy Financial Results for the entire year Ended 2013 At December 31, 2013, the ongoing company had cash, money equivalents and short-term investments of $29.1 million, when compared with $12.5 million at December 31, 2012.The safety, efficacy, and simplicity of the Actamax adhesion barrier was demonstrated in a 78-patient, multi-center clinical research in females undergoing a number of gynecological surgeries. Study results show no critical adverse events and no product-related adverse events, which demonstrate the protection of the product. In this relatively little patient inhabitants the efficacy endpoint also showed a substantial decrease in the incidence, severity and level of adhesions formed. Furthermore, the working surgeons confirmed that the product is simple to use and apply. These results confirm that our fresh adhesion avoidance technology is sound and surgeons with a highly effective solution to minimize patient discomfort and complications.